[Clinical evaluation of aiconol side effects]

Area of Science:

• Nutritional Science
• Biochemistry

Background:

• Atherogenic dyslipidemia is a condition characterized by abnormal lipid profiles.
• Omega-3 polyunsaturated fatty acids (PUFA) are known for their cardiovascular benefits.
• Cod liver oil is a common source of omega-3 PUFA.

Purpose of the Study:

• To investigate the side effects of Aiconol, a cod liver oil concentrate, in patients with atherogenic dyslipidemia.
• To compare the side effects of Aiconol administered in different forms and concentrations.

Main Methods:

• 164 patients with atherogenic dyslipidemia were divided into four groups.
• Group 1 received Aiconol oil (high PUFA, high inert load).
• Groups 2, 3, and 4 received Aiconol in protein caviar, emulsion, and capsules, respectively (lower PUFA, lower inert load).

Main Results:

• Side effects were primarily metabolic, most severe in Group 1 (Aiconol oil).
• Group 1 experienced aggravated gastrointestinal, hepatic, and pancreatic disorders.
• Groups 2, 3, and 4 showed significantly less severe side effects due to reduced PUFA and inert constituents.

Conclusions:

• High doses of omega-3 PUFA and inert constituents in Aiconol oil can lead to metabolic side effects.
• Administering Aiconol in forms with reduced PUFA and inert load mitigates these adverse effects.
• Formulation and dosage are critical factors in managing potential side effects of omega-3 supplements.